Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Aesica Announces Collaboration with QRxPharma

Published: Tuesday, July 23, 2013
Last Updated: Tuesday, July 23, 2013
Bookmark and Share
Agreement for the worldwide promotion of Stealth Beadlets® abuse deterrence technology.

Aesica Pharmaceuticals has announced the signing of an agreement between its subsidiary, Aesica Formulation Development Ltd, and QRxPharma Limited, for the global promotion of QRxPharma’s proprietary Stealth Beadlets® abuse deterrence technology.

Aesica supplies pharmaceutical contract development and manufacturing services internationally and operates six manufacturing sites across the UK, Germany and Italy.

The company provides controlled drug services across the supply chain, for which abuse or diversion may occur, and is actively building relationships for supplying controlled drug APIs and finished dose products to market.

Under the non-exclusive Collaboration Agreement, Aesica will promote QRxPharma’s Stealth Beadlets technology for specific use in controlled drugs formulations.

The company will enter into fee-for-service contracts with customers for the development of the new Abuse Deterrent Formulations (ADF) of specific drugs, whilst QRxPharma will negotiate license terms directly with the Aesica clients concerned.

QRxPharma’s proprietary Stealth Beadlets abuse deterrence technology was developed for the MOXDUO® CR (controlled release) formulation for the treatment of chronic pain.

This programme is ready for Phase 2 studies and has already shown that Stealth Beadlets, incorporated into the Company’s delayed release technology, provide a potential once to twice-a-day formulation.

Work is underway to assure that this ADF technology fully conforms with FDA guidelines for the provision of abuse deterrence statements in product labelling.

Stealth Beadlets can be incorporated into almost any potentially abused drug (e.g. opioids, amphetamines, sedatives, etc.) that are sold in solid dosage forms (e.g. tablet, capsule, sachet). They provide significant resistance against the extraction of active ingredients if crushed, solubilized or heated.

Moreover, Stealth Beadlets have no effect on the active ingredient release profile and consist entirely of patient-safe, low cost, excipients that have GRAS (Generally Regarded As Safe) status with FDA.

Patent applications for the ADF technology are currently under review at the U.S. patent office, and, if granted, will provide for product exclusivity through to 2029.

Alan Raymond, Sales and Marketing Director at Aesica Pharmaceuticals commented: “Aesica is very pleased to have secured this contract with QRxPharma. Indeed, we are committed to providing our customers with the most advanced technologies available for best performance and, consequently, the provision of Stealth Beadlets abuse deterrence technology in formulation development is set to be a highly beneficial addition for our customers in the pharmaceutical and life science markets.”

He continued: “We look forward to making this innovative technology readily available to customers across our international network.”

Remarking on the collaboration, Dr. John Holaday, Managing Director and Chief Executive Officer at QRxPharma, said: “We are delighted to announce our collaboration with Aesica. Their extensive experience in formulation development and contract manufacturing, together with their established client base in the controlled drugs market, creates a wonderful opportunity for our companies to collaborate in the application of our proprietary abuse deterrence technology by third party pharma companies”.

He added: “A head-to-head comparison between Stealth Beadlets and a market leading abuse deterrent technology showed that Stealth Beadlets were more than twice as effective in reducing the percentage of oxycodone that could be extracted from a crushed controlled release tablet.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Aesica Concentrates Investment in Lucrative German Formulations Business
Zwickau site introduces roller compaction unit for dry granulation production.
Saturday, July 12, 2014
Aesica and CMIC Sign Collaborative Agreement
Memorandum of Understanding between the two companies will identify reciprocal consultation and manufacturing opportunities for clients in Japan and Europe whilst enabling joint collaborative development in the US.
Thursday, October 17, 2013
Scientific News
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
First Made-in-Singapore Cancer Drug Enters Clinical Testing
The drug prevents cancer progression and paves the way for new advancements in cancer therapeutics.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!